ASCO/EHA/ICML 2023 – Philipp Staber

Philipp Staber explains the role of functional drug testing in the treatment of patients with hematologic diseases, shares the rationale of the EXALT-2 trial as well as his thoughts on future developments in the field of precision medicine. Finally, he gives insights in the current research topics of the EHA SWG-Precision Hematology and their goal for the next five years.

Here is the full ASCO/EHA/ICML 2023 report.

More posts